Theragnostics, German hospital to study THG-008 for PET

By staff writers

February 17, 2021 -- Theragnostics and Essen University Hospital in Germany will study the investigational agent THG-008 for use in PET imaging of a range of cancers.

The research on the novel F-18 radiolabeled poly (ADP-ribose) polymerase (PARP) inhibitor THG-008 is expected to begin in February 2021. Evidence has already shown that the agent can be used for imaging head and neck cancer. It can detect primary and metastatic head and neck squamous cell carcinoma lesions, and retention in cancer deposits was longer than in healthy tissues.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking